세균성 질염 치료제 시장 규모와 예측, 세계 및 지역 점유율, 동향, 성장 기회 분석 : 유형별, 투여 경로별, 제형별, 유통 채널별, 지역별(2021-2031년)

According to our new research study on "Bacterial Vaginosis Drug Market Forecast to 2031 -Global Analysis - by Type, Route of Administration, Dosage Form, and Distribution Channel, and Geography," the market is anticipated to grow from US$ 2.15 billion in 2024 and is projected to reach US$ 3.82 billion by 2031; it is expected to register a CAGR of 8.3% during 2024-2031. Rising prevalence of bacterial vaginosis, and the increased focus on developing novel and targeted therapies are contributing to the growing Bacterial Vaginosis Drug market size. However, the high recurrence rate and treatment adherence challenges hampers the Bacterial Vaginosis Drug market growth. Further, rising inclination toward microbiome therapies and probiotics are expected to bring in new Bacterial Vaginosis Drug market trends in the coming years.

In terms of revenue, North America dominated the market in 2024. It is estimated to dominate the global market during the forecast period. The US is the largest market for bacterial vaginosis drugs in the world. In the US, the bacterial vaginosis drug market is experiencing significant growth due to the increasing prevalence of BV, rising awareness about women's health, and ongoing efforts for the development of innovative treatments. BV is one of the most common vaginal infections in women, particularly affecting those of reproductive age. According to a report by Medscape in 2024, approximately one-third of adult women in the US, i.e., ~22 million females, are affected by BV annually, and 10 million women visit clinics for abnormal vaginal discharge. It is often linked to factors such as sexual activity, douching, and hormonal changes; nonetheless, there is uncertainty around the exact causes of BV. The primary therapeutic options available for treating BV include antibiotics approved by the US Food and Drug Administration (FDA), such as metronidazole and clindamycin. Metronidazole, often available in oral and topical forms, is considered the first-line treatment for BV. Clindamycin is also commonly available in both oral and topical formulations. Newer drugs and formulations, such as probiotics and phage therapy, are also emerging to help restore the natural vaginal flora, thereby reducing the recurrence of BV.

Government initiatives in the US play a key role in creating and spreading awareness about vaginosis in the population. The National Institutes of Health (NIH) funds research into the causes, treatment, and prevention of BV. The NIH's efforts have led to a deeper understanding of the microbiome and its role in causing BV, which is crucial for developing more targeted therapies. Centers for Disease Control and Prevention (CDC) provide guidelines and recommendations to improve the diagnosis and management of BV. These initiatives help standardize care and ensure that patients receive the most effective treatment. Additionally, the National Institute of Child Health and Human Development (NICHD, a federal agency) and NIH are dedicated to understanding BV and educating women about its causes and prevention. NICHD funds and conducts research on the risks associated with BV and methods for its prevention and treatment.

Bacterial Vaginosis Drug Market Analysis

Strategic Initiatives by Market Players to Provide Market Opportunities in Future

Companies operating in the bacterial vaginosis drugs market constantly focus on strategic developments such as product approvals, collaborations, funding, agreements, and new product launches, which help them improve their sales, increase their geographic reach, and reinforce their capacities to cater to a greater than existing customer base. A few strategic initiatives by key players operating in the bacterial vaginosis drugs market are mentioned below.

In November 2024, Freya Biosciences received US$ 10.4 million in strategic investment from the Bill & Melinda Gates Foundation, with US$ 1.4 million in additional financing from the current investor-Export and Investment Fund of Denmark (EIFO). The company plans to use these funds to develop microbial immunotherapies for the treatment of BV to address the risk of preterm birth along with other indications potentially affecting maternal and newborn health.

In March 2022, Organon and Dare Bioscience, Inc. entered into an agreement whereby Organon will license global rights to XACIATO (clindamycin phosphate vaginal gel, 2%). With this, XACIATO received both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the US Food and Drug Administration (FDA) for the treatment of bacterial vaginosis.

In February 2022, Lupin Pharmaceuticals Inc. received FDA approval for a supplemental New Drug Application (sNDA) to increase the use of SOLOSEC (secnidazole) for the treatment of BV among female patients aged 12 or older; the approval also entailed the treatment of trichomoniasis among patients from the said age group.

In December 2021, the FDA approved XACIATO (clindamycin phosphate vaginal gel, 2%) manufactured by Dare Bioscience, Inc. for the treatment of bacterial vaginosis in females of age 12 years or more.

In February 2021, Rebiotix (Ferring) and MyBiotics collaborated to develop live microbiome-based therapeutics for applications in reproductive medicine and maternal health. This collaboration aims to create live microbiota-based biotherapeutics for bacterial vaginosis among women of childbearing age, which may be associated with the increased risk of miscarriage and complications in pregnancy and fertility.

Therefore, ongoing funding, product launches and approvals, and collaborations are expected to create ample opportunities for the growth of the bacterial vaginosis drugs market in the coming years.

Bacterial Vaginosis Drug Market Report Segmentation Analysis

Key segments that contributed to the derivation of the Bacterial Vaginosis Drug market analysis are type, route of administration, dosage form, and distribution channel.

Based on type, the bacterial vaginosis drug market is segmented into prescription drugs and over-the-counter drugs. The prescription drugs segment held a larger share of the market in 2024.

In terms of route of administration, the bacterial vaginosis drug market is categorized into oral, vaginal, and topical. The oral segment dominated the market in 2024.

In terms of dosage form, the bacterial vaginosis drug market is categorized into pills, creams, gels, solutions/washes, and others. The pills segment dominated the market in 2024.

In terms of distribution channel, the bacterial vaginosis drug market is categorized into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment dominated the market in 2024.

Bacterial Vaginosis Drug Market: Competitive Landscape and Key Developments

Bayer AG, Pfizer Inc, Sanofi SA, Starpharma Holdings Limited, Viatris Inc, Glenmark Pharmaceuticals Ltd, Lupin Ltd, Sun Pharmaceutical Industries Ltd, Organon & Co, Duchesnay Inc., Canada are among the key companies operating in the Bacterial Vaginosis Drug market.

European Journal of Obstetrics & Gynecology and Reproductive Biology, National Institutes of Health, Medscape, Government of Canada, UN World Population Prospects 2024, Eurostat, European Commission, Australian Government's Department of Health and Aged Care, World Bank, and International Trade Administration are among the primary and secondary sources referred to while preparing the Bacterial Vaginosis Drug market report.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Secondary Research
• 3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. Bacterial Vaginosis Drug Market Landscape

• 4.1 Overview
• 4.2 PEST Analysis
• 4.3 Incidence Rate: Bacterial Vaginosis

5. Bacterial Vaginosis Drug Market - Key Market Dynamics

• 5.1 Bacterial Vaginosis Drug Market - Key Market Dynamics
• 5.2 Market Drivers
  • 5.2.1 Rising Prevalence of Bacterial Vaginosis
  • 5.2.2 Increased Focus on Developing Novel and Targeted Therapies
• 5.3 Market Restraints
  • 5.3.1 High Recurrence Rate and Treatment Adherence Challenges
• 5.4 Market Opportunities
  • 5.4.1 Strategic Initiatives by Market Players
• 5.5 Future Trends
  • 5.5.1 Rising Inclination Toward Microbiome Therapies and Probiotics
• 5.6 Impact of Drivers and Restraints:

6. Bacterial Vaginosis Drug Market - Global Market Analysis

• 6.1 Bacterial Vaginosis Drug Market Revenue (US$ Million), 2021-2031
• 6.2 Bacterial Vaginosis Drug Market Forecast Analysis

7. Bacterial Vaginosis Drug Market Analysis - by Type

• 7.1 Prescription Drugs (Rx)
  • 7.1.1 Overview
  • 7.1.2 Prescription Drugs (Rx): Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
• 7.2 Over-the-counter Drugs (OTC)
  • 7.2.1 Overview
  • 7.2.2 Over-the-counter Drugs (OTC): Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)

8. Bacterial Vaginosis Drug Market Analysis - by Route of Administration

• 8.1 Oral
  • 8.1.1 Overview
  • 8.1.2 Oral: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
• 8.2 Vaginal
  • 8.2.1 Overview
  • 8.2.2 Vaginal: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
• 8.3 Topical
  • 8.3.1 Overview
  • 8.3.2 Topical: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)

9. Bacterial Vaginosis Drug Market Analysis - by Dosage Form

• 9.1 Pills
  • 9.1.1 Overview
  • 9.1.2 Pills: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
• 9.2 Creams
  • 9.2.1 Overview
  • 9.2.2 Creams: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
• 9.3 Gel
  • 9.3.1 Overview
  • 9.3.2 Gel: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
• 9.4 Solution or Washes
  • 9.4.1 Overview
  • 9.4.2 Solution or Washes: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
• 9.5 Others
  • 9.5.1 Overview
  • 9.5.2 Others: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)

10. Bacterial Vaginosis Drug Market Analysis - by Distribution Channel

• 10.1 Hospital Pharmacies
  • 10.1.1 Overview
  • 10.1.2 Hospital Pharmacies: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
• 10.2 Online Pharmacies
  • 10.2.1 Overview
  • 10.2.2 Online Pharmacies: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
• 10.3 Retail Pharmacies
  • 10.3.1 Overview
  • 10.3.2 Retail Pharmacies: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)

11. Bacterial Vaginosis Drug Market - Geographical Analysis

• 11.1 North America
  • 11.1.1 North America Bacterial Vaginosis Drug Market Overview
  • 11.1.2 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.1.2.1 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Type
    • 11.1.2.2 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Route of Administration
    • 11.1.2.3 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Dosage Form
    • 11.1.2.4 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Distribution Channel
  • 11.1.3 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
    • 11.1.3.1 North America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
    • 11.1.3.2 United States: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.1.3.2.1 United States: Bacterial Vaginosis Drug Market Breakdown, by Type
      • 11.1.3.2.2 United States: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
      • 11.1.3.2.3 United States: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
      • 11.1.3.2.4 United States: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
    • 11.1.3.3 Canada: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.1.3.3.1 Canada: Bacterial Vaginosis Drug Market Breakdown, by Type
      • 11.1.3.3.2 Canada: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
      • 11.1.3.3.3 Canada: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
      • 11.1.3.3.4 Canada: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
    • 11.1.3.4 Mexico: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.1.3.4.1 Mexico: Bacterial Vaginosis Drug Market Breakdown, by Type
      • 11.1.3.4.2 Mexico: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
      • 11.1.3.4.3 Mexico: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
      • 11.1.3.4.4 Mexico: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
• 11.2 Europe
  • 11.2.1 Europe Bacterial Vaginosis Drug Market Overview
  • 11.2.2 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.2.2.1 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Type
    • 11.2.2.2 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Route of Administration
    • 11.2.2.3 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Dosage Form
    • 11.2.2.4 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Distribution Channel
  • 11.2.3 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
    • 11.2.3.1 Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
    • 11.2.3.2 Germany: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.2.3.2.1 Germany: Bacterial Vaginosis Drug Market Breakdown, by Type
      • 11.2.3.2.2 Germany: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
      • 11.2.3.2.3 Germany: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
      • 11.2.3.2.4 Germany: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
    • 11.2.3.3 United Kingdom: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.2.3.3.1 United Kingdom: Bacterial Vaginosis Drug Market Breakdown, by Type
      • 11.2.3.3.2 United Kingdom: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
      • 11.2.3.3.3 United Kingdom: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
      • 11.2.3.3.4 United Kingdom: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
    • 11.2.3.4 France: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.2.3.4.1 France: Bacterial Vaginosis Drug Market Breakdown, by Type
      • 11.2.3.4.2 France: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
      • 11.2.3.4.3 France: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
      • 11.2.3.4.4 France: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
    • 11.2.3.5 Spain: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.2.3.5.1 Spain: Bacterial Vaginosis Drug Market Breakdown, by Type
      • 11.2.3.5.2 Spain: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
      • 11.2.3.5.3 Spain: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
      • 11.2.3.5.4 Spain: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
    • 11.2.3.6 Italy: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.2.3.6.1 Italy: Bacterial Vaginosis Drug Market Breakdown, by Type
      • 11.2.3.6.2 Italy: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
      • 11.2.3.6.3 Italy: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
      • 11.2.3.6.4 Italy: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
    • 11.2.3.7 Rest of Europe: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.2.3.7.1 Rest of Europe: Bacterial Vaginosis Drug Market Breakdown, by Type
      • 11.2.3.7.2 Rest of Europe: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
      • 11.2.3.7.3 Rest of Europe: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
      • 11.2.3.7.4 Rest of Europe: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
• 11.3 Asia Pacific
  • 11.3.1 Asia Pacific Bacterial Vaginosis Drug Market Overview
  • 11.3.2 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.3.2.1 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Type
    • 11.3.2.2 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Route of Administration
    • 11.3.2.3 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Dosage Form
    • 11.3.2.4 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Distribution Channel
  • 11.3.3 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
    • 11.3.3.1 Asia Pacific: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
    • 11.3.3.2 China: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.3.3.2.1 China: Bacterial Vaginosis Drug Market Breakdown, by Type
      • 11.3.3.2.2 China: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
      • 11.3.3.2.3 China: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
      • 11.3.3.2.4 China: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
    • 11.3.3.3 Japan: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.3.3.3.1 Japan: Bacterial Vaginosis Drug Market Breakdown, by Type
      • 11.3.3.3.2 Japan: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
      • 11.3.3.3.3 Japan: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
      • 11.3.3.3.4 Japan: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
    • 11.3.3.4 India: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.3.3.4.1 India: Bacterial Vaginosis Drug Market Breakdown, by Type
      • 11.3.3.4.2 India: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
      • 11.3.3.4.3 India: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
      • 11.3.3.4.4 India: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
    • 11.3.3.5 Australia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.3.3.5.1 Australia: Bacterial Vaginosis Drug Market Breakdown, by Type
      • 11.3.3.5.2 Australia: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
      • 11.3.3.5.3 Australia: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
      • 11.3.3.5.4 Australia: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
    • 11.3.3.6 South Korea: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.3.3.6.1 South Korea: Bacterial Vaginosis Drug Market Breakdown, by Type
      • 11.3.3.6.2 South Korea: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
      • 11.3.3.6.3 South Korea: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
      • 11.3.3.6.4 South Korea: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
    • 11.3.3.7 Rest of APAC: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.3.3.7.1 Rest of APAC: Bacterial Vaginosis Drug Market Breakdown, by Type
      • 11.3.3.7.2 Rest of APAC: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
      • 11.3.3.7.3 Rest of APAC: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
      • 11.3.3.7.4 Rest of APAC: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
• 11.4 Middle East and Africa
  • 11.4.1 Middle East and Africa Bacterial Vaginosis Drug Market Overview
  • 11.4.2 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.4.2.1 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Type
    • 11.4.2.2 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Route of Administration
    • 11.4.2.3 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Dosage Form
    • 11.4.2.4 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Distribution Channel
  • 11.4.3 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
    • 11.4.3.1 Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
    • 11.4.3.2 Saudi Arabia: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.4.3.2.1 Saudi Arabia: Bacterial Vaginosis Drug Market Breakdown, by Type
      • 11.4.3.2.2 Saudi Arabia: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
      • 11.4.3.2.3 Saudi Arabia: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
      • 11.4.3.2.4 Saudi Arabia: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
    • 11.4.3.3 South Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.4.3.3.1 South Africa: Bacterial Vaginosis Drug Market Breakdown, by Type
      • 11.4.3.3.2 South Africa: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
      • 11.4.3.3.3 South Africa: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
      • 11.4.3.3.4 South Africa: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
    • 11.4.3.4 United Arab Emirates: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.4.3.4.1 United Arab Emirates: Bacterial Vaginosis Drug Market Breakdown, by Type
      • 11.4.3.4.2 United Arab Emirates: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
      • 11.4.3.4.3 United Arab Emirates: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
      • 11.4.3.4.4 United Arab Emirates: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
    • 11.4.3.5 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.4.3.5.1 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Type
      • 11.4.3.5.2 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
      • 11.4.3.5.3 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
      • 11.4.3.5.4 Rest of Middle East and Africa: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
• 11.5 South and Central America
  • 11.5.1 South and Central America Bacterial Vaginosis Drug Market Overview
  • 11.5.2 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
    • 11.5.2.1 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Type
    • 11.5.2.2 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Route of Administration
    • 11.5.2.3 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Dosage Form
    • 11.5.2.4 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Distribution Channel
  • 11.5.3 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
    • 11.5.3.1 South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast Analysis - by Country
    • 11.5.3.2 Brazil: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.5.3.2.1 Brazil: Bacterial Vaginosis Drug Market Breakdown, by Type
      • 11.5.3.2.2 Brazil: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
      • 11.5.3.2.3 Brazil: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
      • 11.5.3.2.4 Brazil: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
    • 11.5.3.3 Argentina: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.5.3.3.1 Argentina: Bacterial Vaginosis Drug Market Breakdown, by Type
      • 11.5.3.3.2 Argentina: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
      • 11.5.3.3.3 Argentina: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
      • 11.5.3.3.4 Argentina: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel
    • 11.5.3.4 Rest of South and Central America: Bacterial Vaginosis Drug Market - Revenue and Forecast to 2031 (US$ Million)
      • 11.5.3.4.1 Rest of South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Type
      • 11.5.3.4.2 Rest of South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Route of Administration
      • 11.5.3.4.3 Rest of South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Dosage Form
      • 11.5.3.4.4 Rest of South and Central America: Bacterial Vaginosis Drug Market Breakdown, by Distribution Channel

12. Industry Landscape

• 12.1 Overview
• 12.2 Growth Strategies in the Bacterial Vaginosis Drug Market
• 12.3 Organic Growth Strategies
  • 12.3.1 Overview
• 12.4 Inorganic Growth Strategies
  • 12.4.1 Overview

13. Company Profiles

• 13.1 Bayer AG
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
• 13.2 Pfizer Inc
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
• 13.3 Sanofi SA
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
• 13.4 Starpharma Holdings Limited
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
• 13.5 Viatris Inc
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
• 13.6 Glenmark Pharmaceuticals Ltd
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
• 13.7 Lupin Ltd
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
• 13.8 Sun Pharmaceutical Industries Ltd
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
• 13.9 Organon & Co
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
• 13.10 Duchesnay Inc., Canada
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments

14. Appendix

• 14.1 About The Insight Partners
• 14.2 Glossary of Terms for Bacterial Vaginosis Drug Market